Overview Vigabatrin for Treatment of Cocaine Dependence Status: Completed Trial end date: 2012-10-01 Target enrollment: Participant gender: Summary The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment. Phase: Phase 2 Details Lead Sponsor: Catalyst Pharmaceuticals, Inc.Treatments: CocaineVigabatrin